Patents by Inventor Eric S. Fischer

Eric S. Fischer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220242872
    Abstract: Provided herein are compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein bind an E3 ubiquitin ligase (e.g., Cereblon) and induce degradation of a transcription factor (e.g., IKZF1, IKZF3). Also provided are pharmaceutical compositions comprising the compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases (e.g., cancers (e.g., carcinoma); leukemia, lung cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, ovarian cancer, colon cancer, colorectal cancer, multiple myeloma, and acute myeloid leukemia (AML))). Further provided are methods of inducing the degradation of a transcription factor (e.g., IKZF1, IKZF3) by administering a compound or composition described herein to a subject and/or to a biological sample (e.g., cell or tissue).
    Type: Application
    Filed: June 23, 2020
    Publication date: August 4, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jun Qi, Eric S. Fischer, Paul M. Park, Chengkui Pei, Radoslaw Piotr Nowak
  • Publication number: 20220062291
    Abstract: Disclosed are compositions and methods of treating cancers by constitutively activating protein phosphatase 2A (PP2A) without blocking signaling through the dopamine D2 receptor, that entail administering a therapeutically effective amount of an analog of perphenazine (PPZ) of formula (I) or (II), or a related PPZ analog lacking dopamine receptor D2 inhibitory activity, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 19, 2019
    Publication date: March 3, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Alfred T. Look, Ken Morita, Eric S. Fischer, Nathanael S. Gray, Shuning He
  • Publication number: 20220047709
    Abstract: Disclosed are bifunctional compounds (degraders) that target Wee1 tyrosine kinase for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 17, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, David Scott, Zhengnian Li, Benika J. Pinch, Calla Olson, Eric S. Fischer, Radoslaw P. Nowak, Katherine A. Donovan
  • Publication number: 20210130368
    Abstract: Disclosed are heterobifunctional compounds that effectuate selective degradation of a target protein, and which include a targeting ligand that binds a target protein and at least one other protein, a ligand that binds an E3 ubiquitin ligase or a component of E3 ubiquitin ligase, and a specificity modulating linker that links the first ligand and the second ligand. Pharmaceutical compositions containing the compounds, and methods of using and making the compounds are also disclosed.
    Type: Application
    Filed: October 19, 2018
    Publication date: May 6, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Radoslaw P. NOWAK, Eric S. FISCHER, Nathanael S. GRAY, Tinghu ZHANG, Zhixiang HE, Brian GROENDYKE
  • Publication number: 20200348285
    Abstract: Presented are methods of assessing the teratogenicity of agents by measuring the degradation of SALL4, and related compounds with reduced teratogenicity. Provided herein is a method for assessing the teratogenicity of an agent comprising: contacting an agent with SALL4; and measuring levels of SALL4, wherein the agent is teratogenic if SALL4 levels are substantially reduced in the presence of the agent relative to in the absence of the agent.
    Type: Application
    Filed: November 9, 2018
    Publication date: November 5, 2020
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Katherine Donovan
  • Patent number: 5511316
    Abstract: A stencil for cutting sandpaper and it is formed from a sheet of plastic transparent plastic material having four corner lips extending down from the corners of the sheet. These corner lips have inner edges that define a rectangular recess for receiving a stack of standard sized sheets of sandpaper. Linear slots and arcuate slots in the stencil allow the sandpaper to be cut into two equal parts, three equal parts, four equal parts or circular disks having 6, 7, and 8 inch diameters.
    Type: Grant
    Filed: September 22, 1994
    Date of Patent: April 30, 1996
    Inventors: Rory T. Fischer, Eric S. Fischer
  • Patent number: 5207348
    Abstract: An auxiliary paint brush bucket that has a planar front wall, an arcuate rear wall and a bottom wall to form an open top container. The front surface of the front wall has a plurality of conical shaped raised bumps thereon formed in a predetermined pattern so that a paint roller may be squeezed against the front wall surface to remove excess paint and it runs down the channels between the respective bumps. A unique pair of laterally spaced clips are formed on the top edge of the rear wall so that it can be removably installed along the inner surface of either a two gallon or five gallon paint bucket.
    Type: Grant
    Filed: June 15, 1992
    Date of Patent: May 4, 1993
    Inventors: Eric S. Fischer, Rory T. Fischer